ZGNX News and Press, Zogenix Inc.

UCB Completes Acquisition of Zogenix, Inc. - Broadens and builds upon UCB's role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy - Total transaction value of up to approximately US$ 1.9 billion / € 1.7 billion. Th...

Three potential deals come to fruition. Healthcare Trust of America to combine with Healthcare Realty Trust in a stock plus cash deal. Chevron to acquire Renewable Energy Group for $3.15 billion, or $61.50 per share, representing a premium of 40.38%. Cedar Realty Trust enters ...

Zogenix Inc. (NASDAQ:ZGNX) traded today at a new 52-week high of $26.66. Approximately 1.2 million shares have changed hands today, as compared to an average 30-day volume of 3.7 million shares. Zogenix Inc. (NASDAQ:ZGNX) defies analysts with a current price ($26.57) 0.4% above its avera...

Two podium and one poster presentation share important new findings on FINTEPLA’s safety profile and its impact on non-seizure related benefits for LGS patients LGS is a debilitating childhood-onset developmental and epileptic encephalopathy estimated to affect approx...

Zogenix press release (NASDAQ:ZGNX): Q4 GAAP EPS of -$0.98 misses by $0.10. Revenue of $26.6M (+212.9% Y/Y) beats by $0.2M. For further details see: Zogenix GAAP EPS of -$0.98 misses by $0.10, revenue of $26.6M beats by $0.2M

Total revenue of $26.6 million in the fourth quarter and $81.7 million for the full year FINTEPLA ® net product sales of $23.5 million in the fourth quarter and $74.7 million for the full year Announced U.S. Food and Drug Administration acceptance with...

NEW YORK, NY / ACCESSWIRE / February 16, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Spirit Airlines, Inc. (NYSE:SAVE...

Symptoms of mitochondrial diseases, such as Thymidine Kinase 2 deficiency (TK2d), can vary widely and mimic other rare and common diseases, making diagnosis challenging 1 , 2 , 3 Genetic testing offers a quicker, confirmatory path to d...

Biotechs struggled in 2021 as indexes lagged the broader market. So far in 2022, biotechs have dropped sharply as interest rate uncertainty has created a risk-off market. A rising interest rate environment remains the biggest risk for biotechs. With the S&P 500 biotech index h...

Zogenix (NASDAQ: ZGNX) stock is having the ride of its life this week -- perhaps for the last time in its history. The biotech announced Wednesday it agreed to be acquired by Belgium-based pharmaceutical company UCB (OTC: UCBJF) . The deal is valued at up to $1.9 billion whe...